Coronary artery disease, global stent market 2008-2017

Coronary artery disease is addressed by a range of alternative treatment methodologies; percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other options, but the use of a wide variety of drug-eluting, drug-coated, bare and bioresorbable stents, constructed of many different material types and designs, represent the fastest growing treatment option and associated medical device market.

The coronary stents market is extremely dynamic by virtue of the relative nascency of the market, particularly for drug-eluting stents (DES; first introduced in 2003). Rapidly growing to a greater than $5 billion market initially dominated by leader Johnson & Johnson’s CYPHER, then Boston Scientific’s TAXUS, drug-eluting stents arguably represent a successful challenge to coronary artery bypass grafting in the treatment of coronary artery disease.

The successes of J&J and Boston Scientific have spurred a stream of newcomers with DES products and other stent types to the market. A range of new stents, with different constructions, material types (including bioabsorbable), coating types and other variations are now at various stages of introduction to the market. 

MedMarket Diligence, drawing on its coverage of coronary stents through the previously published MedMarkets publication and leveraging its expertise in assessing advanced medical technologies markets, is publishing its 2009 report, "Worldwide Market for Drug-Eluting, Bare, Bioresorbable and Other Coronary Stents, 2008-2017. 

MedMarket Diligence’s report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017," details the worldwide market for the use of coronary stents in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types. The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report is being released in April 2009 and is detailed athttp://mediligence.com/rpt/rpt-c245.htm.  The report may be advance ordered (with discount) online at https://mediligence.com/store/page30.html or may be ordered via order form, http://mediligence.com/order_forms/c245_order.pdf.

Medical technology market analysis, worldwide reports

Below is a list of pending or recent reports from MedMarket Diligence. 

 

COMING SOON

Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017

$4,250
(print or PDF; add $200 to receive both)
advance order
 

details

PUBLISHED

Now Published!
Worldwide Surgical Sealants, Glues and Wound Closure Market, 2009-2013

$3,750
(print or PDF; add $200 to receive both)
order

details

New!
Ablation Technologies Worldwide Market, 2008-2017:  Products, Technologies Markets, Companies and Opportunities

$2,950
(print or PDF; add $200 to receive both)
order

details

Spine Surgery Worldwide 2008-2017, 2007-2016:  Products, Technologies, Markets and Opportunities

$2,950
(print or PDF; add $200 to receive both)
order

details

Worldwide Wound Management, 2007-2016:  Established and Emerging Products, Technologies and markets in the U.S., Europe, Japan and Rest of World

$2,850
(print or PDF; add $200 to receive both)
order

details

Worldwide Market for the Clinical Management of Obesity, 2007-2015
(September 2007), report S825

$2,850
(print or PDF; add $200 to receive both)
order

details

 

Drug-eluting, bare, bioresorbable and other coronary stent companies

Coronary stents represent a worldwide market in the $billions due to their potential to address coronary artery disease without the invasive sternotomy, while demonstrating outcomes that rival coronary artery bypass graft procedures, particularly for advanced drug-eluting coronary stents.

Given the financial stakes in the coronary stent market, it has driven the proliferation of competitors seeking to gain shares.  Below are select companies being covered in the 2009 MedMarket Diligence report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."

Aachen Resonance GmbH, Abbott Vascular, AdvanSource Biomaterials, Aeon Bioscience, Amaranth Medical, Inc., amg International GmbH, Arterial Remodeling Technologies (ART), Atrium Medical, Avantec Vascular, B. Braun Melsungen, Balton Ltd., Beijing Lepu Medical Device, Inc., Bioabsorbable Therapeutics, Inc. (BTI), Biocompatibles International plc, Bioring SA, Biosensors International PTE Ltd., Biotronik, Blue Medical Devices B.V., Boston Scientific, Capella Inc., CardioMind, Inc., CeloNova BioSciences, CID (Carbostent & Implantable Devices) SRL, Cinvention AG (Formerly Blue Membranes), CorNova, CV Therapeutics, Devax, DISA Vascular, DSM Biomedical/Caliber Therapeutics, Elixir Medical Corporation, Estracure, eucatech AG, Eurocor GmbH, Genesis Technologies, LLC, Global Therapeutics (Cook Medical), Hexacath, ICON Interventional Systems, InspireMD, InTek Technology, Invatec S.p.A., ITGI Medical Ltd., Johnson & Johnson (Cordis, Conor Medsystems), JW Medical Systems/Biosensors International, Kaneka Corporation, Kyoto Medical Planning Co., Ltd., Lutonix, Medinol/ARIAD Pharmaceuticals, Medlogics Device Corporation (MDC), Medtronic Vascular, Miami Cardiovascular Innovations (MCVI), Micell Technologies, MicroPort Scientific Corporation, Minvasys, MIV Therapeutics (Biosync Scientific Pvt. Ltd.), mNEMOSCIENCE GmbH, NanoInterventions, LLC, Neovasc Inc., Nexeon MedSystems, Inc., Opto Circuits Ltd., OrbusNeich, Picarus NV, Possis Medical, Prescient Medical, Relisys Medical Devices, REVA Medical, Sahajanand Medical Technologies, Stentys, Terumo, Translumina, TriReme Medical, Tryton Medical, Vascular Concepts, VasoTech, Inc., X-Cell Medical, Xtent.


Purchase for download:  Report #C245, "Worldwide Coronary Stents 2009, PDF" — $2,850.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

Drug-Eluting Balloon Catheters

[Through the course of researching and analyzing coronary artery disease treatments, technologies and markets for our May 2009 worldwide coronary stents market report, we have compiled data on the ancillary market of drug-eluting balloons, which we synopsize below.]

Drug-Eluting Balloons

A handful of companies are developing drug-coated balloon catheters as an alternative to balloon angioplasty and stenting and for those who would not benefit from PCI, such as those in whom antiplatelet therapy is neither recommended nor desired. 

The concept behind the technology is based on the assumption that delivering a rapid release of drugs into the arterial tissue is more effective than the gradual release of drugs, as seen with drug-eluting stents. Another side benefit of the technology would be significant cost-savings. Angioplasty balloons currently used typically cost roughly $400 each.

[ad#ad-3]

Technologies/approaches being developed by specific companies include:

  • drug-coated angioplasty catheters for coronary and peripheral applications
  • development of paclitaxel-coated angioplasty catheter
  • coating standard angioplasty balloons with paclitaxel
  • bioabsorbable coating on balloon drug-eluting balloon catheter
  • mix of paclitaxel and hydrophilic spacer on balloon surface
  • paclitaxel-eluting balloon catheter for in-stent restenosis, bifurcated lesions, small diameter lesions, etc.
  • polymer-based drug delivery on balloon catheter
  • paclitaxel-eluting balloon catheter with controlled drug release for coronary and peripheral applications
  • drug-eluting balloon catheter with surface that penetrates, splits stenosis to facilitate drug delivery

 

 Developers of Paclitaxel-Eluting Balloon Catheters

See report #C245 for table of companies with products in development

Source:  MedMarket Diligence report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017." May 2009. 


Purchase for download:  Report #C245, "Worldwide Coronary Stents 2009, PDF" — $2,850.00
themesmedia/tab_blue_button_add.gif  themesmedia/tab_blue_button_view.gif

Clinical trials on coronary stents (drug-eluting, bare, resorbable)

There is a wide range of clinical trials evaluating drug-eluting, bare, and resorbable coronary stents for their safety, efficacy and performance.  Below are many of the key trials in process or completed.

 

ABSORB
HORIZONS-AMI
ARRIVE II Registry
ISAR, ISAR-TEST-2
ARTS
LONG DES
AXXESS PLUS
NOBLESS
BASKET
NOBORI
BBC ONE
NORDIC
CARE
OLYMPIA Registry
COREL
PASSION
COSTAR
PREPARE
COURAGE
PROGRESS
CUSTOM
RESOLUTE
DEScover Registry
RESORB
DIRECT
REWARD Registries
DIVERGE
SERIES
e-HEALING
SIMPLE Registries
EASTER Registry
SIRIUS, E-SIRIUS, C-SIRIUS
ENDEAVOR
SORT-OUT III
ETHOS
SPIRIT
EuroSTAR
STEALTH
EVENT Registry
STEMI
FAME
STENT Registry
GENESIS
SVELT
FOCUS
TAXUS
HEALING
TYPHOON

Source: Report #C245, "Worldwide Coronary Stents, 2009-2018."


These trials are described in the business market analysis from MedMarket Diligence, LLC, Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017," publishing March/April 2009.

This report details the worldwide market for the use of coronary stents in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types. The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.